DCM
ACRV icon

DAFNA Capital Management’s Acrivon Therapeutics ACRV Stock Holding History

DAFNA Capital Management’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-112,414
Closed -$677K – 84
2024
Q4 		$677K Hold
112,414
– – 0.17% 69
2024
Q3 		$787K Sell
112,414
-8,937
-7% -$70.4K 0.19% 66
2024
Q2 		$704K Sell
121,351
-10,000
-8% -$80.5K 0.17% 68
2024
Q1 		$939K Hold
131,351
– – 0.21% 61
2023
Q4 		$646K Buy
131,351
+54,499
+71% +$288K 0.15% 63
2023
Q3 		$735K Hold
76,852
– – 0.23% 62
2023
Q2 		$996K Buy
76,852
+25,704
+50% +$311K 0.27% 53
2023
Q1 		$649K Buy
51,148
+35,500
+227% +$596K 0.19% 57
2022
Q4 		$180K Buy
+15,648
New +$199K 0.05% 74

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DAFNA Capital Management's ACRV Position: Q1 2025 in Review

DAFNA Capital Management sold out of Acrivon Therapeutics (ACRV) in Q1 2025, closing a stake of 112,414 shares — an estimated $677K sold.

DAFNA Capital Management first reported a position in ACRV in Q4 2022 and held it in 9 quarters. The position peaked at $996K in Q2 2023. 63 funds tracked by Wall St. Rank hold ACRV as of Q1 2025.

  • DAFNA Capital Management reported no remaining Acrivon Therapeutics position as of Q1 2025 after selling out during the quarter.
  • DAFNA Capital Management sold 112,414 Acrivon Therapeutics shares in Q1 2025, an estimated $677K.
  • DAFNA Capital Management first reported a position in Acrivon Therapeutics in Q4 2022 and held it in 9 quarters.
  • DAFNA Capital Management's Acrivon Therapeutics position peaked at $996K in Q2 2023.
  • 63 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2025.

Based on DAFNA Capital Management's 13F filing for Q1 2025, filed 15 May 2025.